摘要
目的 探索合适的门脉局部给药治疗门脉高压症的途径。方法 采用四氧化碳 (CCl4 )诱发的鼠肝硬化门脉高压模型。将哌唑嗪分别从下腔静脉、门静脉、肝动脉输注和脾直接穿刺给药 ,比较4种途径给药后门脉压 (PVP)、下腔静脉压 (ICVP)、平均动脉压 (MAP)和心率 (HR)的变化情况。结果 哌唑嗪经门脉、肝动脉和脾脏注入使PVP平均下降 18.6 %、18.6 %和 14.8% ,三者无明显差别 ,明显高于下腔静脉注入 ,后者平均下降 10 .3% ,经门脉、肝动脉和脾脏注入使MAP下降分别为 :12 .4%、14.5 %和 18.9% ,明显低于下腔静脉注入 ,后者使MAP下降 2 4.1%。 4种途径对心率的影响无差别。结论 哌唑嗪经肝动脉和脾脏注入同样具有经门脉注入治疗门脉高压的优点 ,即降门脉压作用强 ,对全身血流动力学影响小 ;肝动脉植泵注入扩血管性降门脉压药物是临床上可采用的药物治疗门脉高压的方法。
Objective To find out the ideal portal vein targetting injection routes for portal hypertension treatment.Methods 28 cirrhotic rat models with portal hypertension induced by CCl 4 were divided into 4 groups: inferior caval vein injection group, portal vein injection group, hepatic artery injection group, spleen injection group. The changes in portal vein pressure (PVP), inferior caval vein pressure (ICVP), mean artery pressure (MAP) and heart rate (HR) were monitored before and after prazosin injection. Results After intraportal, intra hepatic arterial or spleen injection of prazosin, larger decrease in PVP and lesser effects on MAP than intravenous injection had been induced. The effect on HR showed no difference among these four groups. Conclusions Hepatic artery and spleen prazosin administration have the same advantages on treatment of portal hypertension as those of intraportal infusion, that is the greater decrease on portal vein pressure, the lesser effects on systemic hemodynamics. Vasodilation drugs for hepatic artery infusion through percutaneous port catheter system by hepatic artery implantation would be an ideal method for portal hypertension treatment.
出处
《介入放射学杂志》
CSCD
2002年第2期114-116,共3页
Journal of Interventional Radiology
